Dr. Reddy’s Laboratories Acquires Rights to STUGERON from Johnson & Johnson for CNS Portfolio Expansion

Dr. Reddy’s Laboratories has finalized an agreement with Johnson & Johnson to acquire the rights to STUGERON, a medication used in the central nervous system (CNS) therapeutic area. The acquisition includes the locally recognized brands STUGERON and STUGERON FORTE, further expanding Dr. Reddy’s portfolio in this segment.

The transaction marks a strategic move by Dr. Reddy’s to strengthen its presence in the CNS market. While specific financial details of the deal have not been disclosed, the acquisition is expected to enhance the company’s offerings in neurological treatments. STUGERON is widely known for its use in managing conditions such as vertigo and motion sickness, and its addition aligns with Dr. Reddy’s focus on addressing unmet medical needs within this therapeutic category.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 11, 2025

Author

Mark Chiang